Literature DB >> 26856742

Health policy: Putting a price on cancer.

Richard Sullivan1, Ajay Aggarwal2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26856742     DOI: 10.1038/nrclinonc.2016.12

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  12 in total

1.  Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.

Authors:  Sabine Vogler; Agnes Vitry; Zaheer-Ud-Din Babar
Journal:  Lancet Oncol       Date:  2015-12-04       Impact factor: 41.316

Review 2.  Foreign free riders and the high price of US medicines.

Authors:  Donald W Light; Joel Lexchin
Journal:  BMJ       Date:  2005-10-22

3.  Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.

Authors:  Tito Fojo; Sham Mailankody; Andrew Lo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-12       Impact factor: 6.223

4.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; E G E de Vries; M J Piccart
Journal:  Ann Oncol       Date:  2015-05-30       Impact factor: 32.976

5.  Cancer drugs in the United States: Justum Pretium--the just price.

Authors:  Hagop M Kantarjian; Tito Fojo; Michael Mathisen; Leonard A Zwelling
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

6.  Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries.

Authors:  Kalipso Chalkidou; Patricio Marquez; Preet K Dhillon; Yot Teerawattananon; Thunyarat Anothaisintawee; Carlos Augusto Grabois Gadelha; Richard Sullivan
Journal:  Lancet Oncol       Date:  2014-02-14       Impact factor: 41.316

7.  Achieving health equity: from root causes to fair outcomes.

Authors:  Michael Marmot
Journal:  Lancet       Date:  2007-09-29       Impact factor: 79.321

8.  Economic Burden of Bladder Cancer Across the European Union.

Authors:  Jose Leal; Ramon Luengo-Fernandez; Richard Sullivan; J Alfred Witjes
Journal:  Eur Urol       Date:  2015-10-25       Impact factor: 20.096

9.  Economic burden of cancer across the European Union: a population-based cost analysis.

Authors:  Ramon Luengo-Fernandez; Jose Leal; Alastair Gray; Richard Sullivan
Journal:  Lancet Oncol       Date:  2013-10-14       Impact factor: 41.316

Review 10.  Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Authors:  Courtney Davis
Journal:  Soc Sci Med       Date:  2014-12-02       Impact factor: 4.634

View more
  1 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.